IZAFE GROUP AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.222 SEK | 0.00% |
|
+3.74% | -22.92% |
| 26/04 | IZafe Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 15/04 | IZafe Group AB Announces Ida Almgren to Step Down as CFO , Effective June 18, 2024 | CI |
| Sales 2022 | 7L 69.43T 57.92L | Sales 2023 | 18.22L 2L 1.45Cr | Capitalization | 7.22Cr 68.74L 57Cr |
|---|---|---|---|---|---|
| Net income 2022 | -2.3Cr -21.91L -18Cr | Net income 2023 | -3.2Cr -30.48L -25Cr | EV / Sales 2022 | 36.3 x |
| Net Debt 2022 | 22.98L 2L 1.83Cr | Net cash position 2023 | 33.1L 3L 2.63Cr | EV / Sales 2023 | 37.8 x |
| P/E ratio 2022 |
-0.99
x | P/E ratio 2023 |
-2.07
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 13.76% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +3.74% | ||
| Current month | -4.72% | ||
| 1 month | +1.37% | ||
| 3 months | +1.37% | ||
| 6 months | -12.94% | ||
| Current year | -22.92% |
1 week
0.21
0.23
1 month
0.210.24
Current year
0.200.31
1 year
0.170.48
3 years
0.173.80
5 years
0.175.18
10 years
0.1718.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 39 | 01/19/01 | |
Ida Almgren
DFI | Director of Finance/CFO | - | 09/20/09 |
Erik Gillsbro
CTO | Chief Tech/Sci/R&D Officer | 33 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Björn Rosengren
CHM | Chairman | 82 | 14/13/14 |
Göran Hermansson
BRD | Director/Board Member | 71 | 01/19/01 |
Richard Wolff
BRD | Director/Board Member | 49 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 0.222 | 0.00% | 5 000 |
| 17/24/17 | 0.222 | +2.78% | 77,979 |
| 14/24/14 | 0.216 | -1.82% | 24,469 |
| 13/24/13 | 0.22 | -1.79% | 159,349 |
| 12/24/12 | 0.224 | +4.67% | 31,766 |
Delayed Quote Nasdaq Stockholm, June 18, 2024 at 03:57 pm IST
More quotes
iZafe Group AB, formerly MediRatt AB, is a Sweden-based company that conducts research, development and marketing of medical products for medication and drug management. Its offering includes Dosell, a patented drug dispenser under development that can be used when medicating patients at home via remote monitoring; and MediKoll, an app that provides patients information about side effects, reactions and allergies linked to different types of medication. The Company operates in the pharmaceutical industry, hospitals and care homes, and Pharmacies and private healthcare markets. It is active globally.
Calendar
30/08/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -22.92% | 58.18L | |
| +7.01% | 22TCr | |
| +9.85% | 19TCr | |
| +27.51% | 15TCr | |
| +31.79% | 11TCr | |
| -0.84% | 6.28TCr | |
| +13.93% | 5.23TCr | |
| +1.85% | 4.93TCr | |
| +0.30% | 3.54TCr | |
| +22.28% | 3.09TCr |
- Stock Market
- Equities
- IZAFE B Stock
